Overview Rituximab for the Treatment of Severe Ocular Manifestations of Behcet's Disease Status: Completed Trial end date: 2008-01-01 Target enrollment: Participant gender: Summary The purpose of this study is to find if Rituximab can improve severe ocular lesions of Behcet's Disease. Phase: Phase 2 Details Lead Sponsor: Tehran University of Medical SciencesCollaborator: Hoffmann-La RocheTreatments: Rituximab